Skip to main content


Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study

Fig. 3

Time to Resolution of Influenza-Like Symptoms in Subjects <50 Years Without Related Ongoing Disease. Analysis carried out in the intent-to treat analysis set. Note: Time to resolution was the total number of days from randomisation to the first instance at which all influenza-like symptoms had a score of 0 (date of resolution of all influenza-like symptoms minus the date of randomisation + 1)

Back to article page